Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating

Viking Therapeutics, Inc. (NASDAQ:VKTX) ranks among the best abbreviated compression stocks to bargain close now. On November 20, H.C. Wainwright retained its Buy standing and $102 terms people for Viking Therapeutics, Inc. (NASDAQ:VKTX) pursuing the extremity of enrollment successful the company’s VANQUISH-1 obesity trial.

Copyright: dolgachov / 123RF Stock Photo

The trial, which enrolled astir 4,650 individuals, concluded up of docket and volition comparison 3 antithetic doses to a placebo implicit a 78-week period. VANQUISH-2, the company’s 2nd trial, which aims to enroll astir 1,100 radical with benignant 2 diabetes who hap to beryllium obese oregon overweight, is inactive enrolling and is expected to beryllium completed successful the archetypal 4th of 2026.

Viking Therapeutics, Inc. (NASDAQ:VKTX) besides released exploratory investigation information from its Phase 2 VENTURE proceedings astatine ObesityWeek 2025 connected November 6, demonstrating important improvements successful cardiometabolic measures among obese patients. Notably, 78% of prediabetic individuals who received VK2735 had mean glycemic power aft 13 weeks, arsenic opposed to 29% successful the placebo group.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is simply a clinical-stage biopharma institution processing treatments for metabolic and endocrine disorders, including obesity, NASH, and uncommon diseases similar X-linked adrenoleukodystrophy (X-ALD).

While we admit the imaginable of VKTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.